Seaport Therapeutics Said to Raise $255 Million in IPO

Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range, according to people familiar with the matter.
Source
Bloomberg Markets
Opens original article in a new tab

